KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
KalVista Pharmaceuticals presented sebetralstat data at Bradykinin Symposium 2024, showing consistent efficacy and safety profiles across phase 2 and 3 trials, with rapid symptom relief and a safety profile comparable to placebo. Median time to treatment was 9 minutes for all attacks and 8 minutes for laryngeal attacks, with median time to symptom relief at 1.8 hours for all attacks and 1.3 hours for laryngeal attacks. Oral sebetralstat may address challenges of current injectable treatments for HAE.
Reference News
KalVista Pharmaceuticals presented sebetralstat data at Bradykinin Symposium 2024, showing consistent efficacy and safety profiles across phase 2 and 3 trials, with rapid symptom relief and a safety profile comparable to placebo. Median time to treatment was 9 minutes for all attacks and 8 minutes for laryngeal attacks, with median time to symptom relief at 1.8 hours for all attacks and 1.3 hours for laryngeal attacks. Oral sebetralstat may address challenges of current injectable treatments for HAE.